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A B S T R A C T
Liquid-based cytology (LBC) enables the use of supplementary methods in the diagnosis and prognosis of cervical le-
sions. The aim of this study was to analyze the correlation between p16INK4a immunoexpression in ThinPrep cervical cyto-
logic samples and human papillomavirus (HPV) detection by polymerase chain reaction (PCR) from the same sample.
LBC-ThinPrep (Cytyc, USA) cervical cytology samples, prepared and stained by Papanicolaou method, were analyzed
using modified Bethesda cytologic classification named »Zagreb 2002«. A second ThinPrep slide, prepared from the
same sample, was immunostained for p16INK4a using CINtec p16INK4a Cytology Kit (DakoCytomation, Denmark). In-
creased expression of the high-risk (HR) HPV E6 and E7 oncogenes results in a highly specific increase in p16 protein ex-
pression and overexpression of p16INK4a acts as a potential biomarker for cervical cancer progression from premalignant
lesions. Brown nuclear and/or cytoplasmic staining of abnormal cells was considered a positive result. Residual mate-
rial was used for 13 HRHPV-DNA detection by the PCR based AMPLICORHPV test (Roche Molecular Systems). A total
of 120 ThinPrep Pap tests with the following cytologic diagnoses: 17 within normal limits, 17 atypical squamous cell
(ASC) (7 ASC of undetermined significance /ASCUS/ and 10 ASC of high-grade squamous intraepithelial lesions can-
not be excluded /ASC-H/), 26 low-grade squamous intraepithelial lesions (LSIL) corresponding cervical intraepithelial
neoplasia (CIN) I, 57 high-grade SIL (HSIL) i.e. 24 CIN II and 33 CIN III and 3 squamous cell carcinoma (SCC) were
included in the study. All CIN III (n=33) and SCC (n=3) specimens expressed p16INK4a immunoreactivity, whereas the
HR HPV test was positive in 97% (32/33) of CIN III and 100% (3/3) of SCC specimens. The p16INK4a biomarker was posi-
tive in 87.5% (21/24) of CIN II and 69% (18/26) of CIN I, while the HR HPV was positive in 75% (18/24) of CIN II and
50% (13/26) of CIN I. In ASCUS cytology, p16INK4a and HR HPV showed the same rate of positivity (28.5%; 2/7). Expres-
sion of p16INK4a was detected in all cytologic (10/10) ASC-H lesions, in contrast to HR HPV detected in only 20% (2/10) of
ASC-H cases. These data suggest the p16INK4a evaluation in ThinPrep cervical samples to be significantly associated
with HR HPV testing by PCR in the same sample for the diagnosis of HSIL lesions and cervical carcinomas. A prospec-
tive study with longer follow up may clarify the predictive values in the management of LSIL and ASC diagnosis.
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Introduction
The Papanicolaou (Pap) test has been the most suc-
cessful cancer screening test in the history of modern
medicine. Since its introduction in the 1940s, the conven-
tional Pap test has dramatically decreased the morbidity
and mortality of cervical cancer by identifying and classi-
fying cellular and morphological changes associated with
progression to cancer, but the disease has not been era-
dicated1,2. Among other factors, particularly sampling er-
rors, the inadequate efficiency of the screening program
results also from inaccurate cytology findings, largely be-
cause the evaluation of the Pap test relies on individual
subjective diagnostic skills and experience3,4. This indi-
cates the need for adjunct methods, among them
liqid-based cytology (LBC)5,6 and specific biomarkers
(p16INK4a, L1)7–11. LBC has been developed in the last few
decades as an alternative to conventional cytology re-
porting to increase the sensitivity of cervical cytology
and the proportion of slides that are satisfactory for
assessment5,6,12–15. LBC slides can be read more quickly
than conventional cytology slides15 and the liquid sample
can be used for human papillomavirus (HPV) DNA test-
ing and for other molecular tests16–19. Epidemiological
studies have clearly established that persistent infection
with high-risk human papillomavirus (HR HPV) is the
primary risk factor for the development of cervical can-
cer and its precursor lesions20–23. However, HR HPV can-
not accurately discriminate patients whose squamous
intraepithelial lesions (SIL) will persist or progress to in-
vasive carcinoma from those whose lesions will regress
spontaneously. It has been proposed that p16INK4a is a
useful biomarker for the identification of cervical intraepi-
thelial lesions (CIN) because it is a measure of persistent
HPV infection rather than viral presence only7–9,26–28.
p16INK4a as a specific inhibitor of the cycline-dependent
kinase (cdk4 and cdk6) plays a crucial role in the regula-
tion of the cell cycle (the G1 checkpoint) by retinoblas-
toma protein phosphorylation24,25. Increased expression
of the HR HPV E6 and E7 oncogenes through binding to
the retinoblastoma protein and release of transcription
factor E2F results in a highly specific increase in p16INK4a
protein expression in dysplastic and malignant cells of
squamous and columnar epithelium of the cervix, which
is detectable by a specific monoclonal antibody26–28.
The aim of the present study was to analyze the corre-
lation between p16INK4a immunoexpression in ThinPrep
cervical cytologic samples and HPV detection by poly-
merase chain reaction (PCR) in the same sample.
Materials and Methods
Specimen preparation and processing
During the one-year study period (January to Decem-
ber 2008), a total of 120 cervical cytology specimens were
received at the University Department of Gynecology
and Obstetrics, University Hospital Center Zagreb.
ThinPrep (Cytyc Corp., Boxborough, Massachusetts,
USA) cervical cytology samples (N=120) were prepared
according to the instruction detailed in the ThinPrep
2000 operator’s manuals within 6 weeks of the specimen
collection date. Cell sample obtained by Cervex-Brush
(Rovers Medical Devices B.V., Oss, The Netherlands),
from exocervix and endocervical canal was thoroughly
washed in a vial containing PreservCyt solution. At the
laboratory, the PreservCyt sample vial is placed into a
ThinPrep 2000 Processor and a gentle dispersion step
breaks up blood, mucus, non-diagnostic debris, and thor-
oughly mixes the cell sample. The cells are then collected
on a ThinPrep Pap Test Filter specifically designed to
collect diagnostic cells. The Processor constantly moni-
tors the rate of flow through the filter during the collec-
tion process in order to prevent the cellular presentation
from being too scant or too dense. A thin layer is then
transferred to a glass slide in a 20 mm-diameter circle,
and the slide is automatically deposited into a fixative so-
lution. One slide was stained with Papanicolaou and ana-
lyzed using modified Bethesda cytologic classification
named »Zagreb 2002«29.
Immunocytochemistry
A second ThinPrep slide, prepared from the same
sample, was fixed for at least 48h in 96% ethyl alcohol,
followed by postfixation in 50% ethyl alcohol and ace-
tone, and then immunostained for p16INK4a using CINtec
p16INK4a Cytology Kit (DakoCytomation, Denmark). Ac-
cording to its protocol, immunocytochemistry was per-
formed as follows: »cooking« in Epitope Retrieval Solu-
tion at 96 °C; cooling down in dark chamber; discarding
of excessive Epitope Retrieval Solution; and rinsing in di-
luted Wash Buffer. Then the slides were placed in the
DakoCytomation Autostainer for the following automa-
ted procedure: peroxidase blocking (peroxidase blocking
reagent), addition of the mouse anti-human p16INK4a and
visualization reagent, rinsing and immersion in the sub-
strate-chromogen solution (DAB). Upon immunocyto-
chemistry staining in the Autostainer, the samples were
counterstained with hematoxylin, standard embedded,
and analyzed by microscopy. Brown-colored cells (nu-
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Fig. 1. High-grade squamous intraepithelial lesions (HSIL) in
ThinPrep specimen (cervical intraepithelial neoplasia /CIN/ III
on follow up histology), Papanicolaou, X200.
clear and/or cytoplasmic staining) indicated p16INK4a
overexpression. Their number varied from case to case.
Figure 1 provides representative images of high-grade
SIL (HSIL) or CIN III on ThinPrep specimen and Figure
2 strong nuclear staining by the p16INK4a immunocyto-
chemistry assay.
HPV testing
Residual material was used for HR HPV-DNA detec-
tion by the PCR based AMPLICOR HPV test (Roche Mo-
lecular Systems). The test is designed to amplify HPV
DNA from 13 high-risk genotypes (16,18,31,33,35,39,
45,51,52,56,58,59 and 68). The test amplifies 165 bp long
nucleotide sequence within the polymorphic L1 region of
the HPV genome with a master mix containing biotin la-
beled primers. An additional primer pair is added to al-
low for simultaneous amplification of the human ß-glo-
bin gene, which allows for assessment of cellular ade-
quacy.
Results
A total of 120 ThinPrep Pap tests were included in
this study representing the following cytologic diagnosis:
17 within normal limits, 17 atypical squamous cell (ASC)
(7 ASC of undetermined significance /ASCUS/ and 10
ASC of HSIL cannot be excluded /ASC-H/), 26 low-grade
SIL (LSIL) – CIN I, 57 HSIL – 24 CIN II and 33 CIN III
and 3 squamous cell carcinoma (SCC). All CIN III (n=33)
and SCC (n=3) specimens expressed p16INK4a immuno-
reactivity, whereas the HR HPV test was positive in 97%
(32/33) of CIN III and 100% (3/3) of SCC specimens. The
p16INK4a biomarker was positive in 87.5% (21/24) of CIN
II and 69% (18/26) of CIN I, while HR HPV was positive
in 75% (18/24) of CIN II and 50% (13/26) of CIN I. In
ASCUS cytology, p16INK4a and HRHPV showed an identi-
cal rate of positivity (28.5%; 2/7). Expression of p16INK4a
was detected in all cytologic (10/10) ASC-H lesions, in
contrast to HR HPV detected in only 20% (2/10) of
ASC-H cases (Table 1 and Figure 3). Table 2 summarizes
the overall results for p16INK4a and HR HPV status
within the cytologic categories of ASCUS and LSIL.
Positivity of both tests was found in 14.3% (1/7) of
ASCUS and in 33.3% (8/24) of LSIL lesions, while both
tests were negative in 57.1% (4/7) of ASCUS and 12.5%
(3/24) of LSIL cases (Table 2).
Histopathologic verification (biopsy) performed in
35% (42/120) of abnormal cytologic findings confirmed
HSIL (CIN II and CIN III) in 73.3% (22/30) of cases; CIN I
was detected in one case; and negative biopsy finding was
recorded in 7 cases. Out of 23% (6/26) of cytologic find-
ings of CIN I, biopsy confirmed it in 3 cases; CIN II was
verified by histopathology in one case; and the remaining
two biopsy specimens were negative. Out of 4 cytologic
findings of ASC-H (4/10) submitted to histopathology,
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TABLE 1
p16INK4a TEST AND HR-HPV TEST ACCORDING TO
THE CYTOLOGICAL DIAGNOSIS
Total
N
p16INK4a
positive
N (%)
HR-HPV
positive
N (%)
Normal 17 0 (0.0) 5 (23.5)
ASCUS 7 2 (28.5) 2 (28.5)
ASC-H 10 10 (100.0) 2 (20.0)
LSIL (CIN I) 26 18 (69.0) 13 (50.0)
HSIL (CIN II) 24 21 (87.5) 18 (75.0)
HSIL (CIN III) 33 33 (100.0) 32 (97.0)
SCC 2 2 (100.0) 2 (100.0)
Total 120 86 (71.6) 74 (61.6)
HR – high-risk, HPV – human papillomavirus, ASCUS – atypi-
cal squamous cells of undetermined significance, ASC-H – atypi-
cal squamous cells – HSIL cannot be excluded, LSIL – low-grade
squamous intraepithelial lesions, HSIL – high-grade squamous
intraepithelial lesions, CIN – cervical intraepithelial neoplasia,
SCC – squamous cell carcinoma
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Fig. 3. p16INK4a test and high-risk human papillomavirus (HR
HPV) test according to cytologic diagnosis. ASCUS – atypical
squamous cells of undetermined significance, ASC-H – atypical
squamous cells – HSIL cannot be excluded, LSIL – low-grade
squamous intraepithelial lesions, HSIL – high-grade squamous
intraepithelial lesions, CIN – cervical intraepithelial neoplasia,
SCC – squamous cell carcinoma.
Fig. 2. p16INK4a positive staining of high-grade squamous
intraepithelial lesions (HSIL), X200.
CIN III and microinvasive SCC (MIC) were found in one
case each, whereas the remaining two findings were neg-
ative.
Discussion
LBC has been compared with conventional cytology
in many studies and several systematic reviews, and
their conclusions have been disparate5,6,12–15,30–32. Studies
comparing test positivity rates for low-grade cytologic
abnormalities often yielded more favorable results for
LBC12,14, whereas in studies focusing on accuracy for bi-
opsy-confirmed CIN, no significant differences were
found between the conventional Pap and LBC30,31. In
some countries, LBC has been officially adopted for cer-
vical cancer screening because studies conducted in tho-
se countries showed LBC to be more often satisfactory
than Pap smears. This is the case, for instance, in the
NICE report from UK, where 7–10% of the conventional
Pap smears were unsatisfactory33. In our country, Pap
smears are taken by trained gynecologists and we have
very few unsatisfactory smears (0.04% at our Depart-
ment, 2005). Although there is no evidence that LBC is
more accurate than conventional cytology, equivalent
performance might be sufficient if LBC has other advan-
tages, such as reducing the reading times, if it is more ap-
propriate for automated screening devices and offers an
opportunity for concurrent HPV DNA testing and immu-
nocytochemistry. Morphological interpretation of ASCUS
and LSIL shows significant inter-observer discrepancies,
so additional methods could be really useful for triage of
patients with these cytologic categories34,35. HPV testing
is more sensitive, but less specific for detecting cervical
neoplasia than conventional cytology36,37. HPV testing is
less specific than cytology because many infections re-
gress without developing high-grade lesions. Previous
studies have reported that the introduction of the
p16INK4a biomarker together with HR HPV testing can
increase specificity while maintaining sensitivity7–9,
26–28,38. p16 overexpression has been shown to be associ-
ated with progression to CIN III or cancer39,40.
A total of 120 ThinPrep specimens with another
ThinPrep slides prepared from the same LBC samples
immunocytochemically stained for p16INK4a were evalu-
ated at our Department for the first time in Croatia.
Using this protocol, we obviated destaining and repeat
immunocytochemical staining of the conventional Pap
smear for p16INK4a. Namely, ThinPrep specimens applied
in a thin layer and with a lower content of blood, inflam-
matory cells and mucus are by far more suitable for anal-
ysis and reaction reading off41. The remaining LBC ma-
terial left over after cytologic analysis was adequate for
HR HPV PCR typing in all cases.
Our results pointed to good correspondence between
positive p16INK4a staining and grade of intraepithelial le-
sion (the rate of positivity increased from 69.0% in CIN I
through 87.5% in CIN II to up to 100% in CIN III) and
good correlation with HR HPV PCR typing (50% in CIN
I, 75% in CIN II, and 97% in CIN III), which is consistent
with literature reports7–9,42, where the rate of p16INK4a
positivity ranged from 42% to 78% in LSIL and from 81%
to 96% in HSIL. Unlike some of these reports42, in our
ThinPrep LSIL specimen total positive expression of
p16INK4a was higher than HR HPV typing (69% vs. 50%).
In our three SCC cases, we found diffuse and highly posi-
tive reaction to p16INK4a and presence of HR HPV8,9,
26–28,41. Our cytologically negative ThinPrep specimens
also showed negative reaction to p16INK4a, in contrast to
positive HR HPV typing in 23.5% of the same specimens.
In comparison with other studies reporting on up to 10%
of positive HR HPV findings in normal cytologic fin-
dings43, the higher results obtained in the present study
could be explained by the majority of our patients to have
previously had one or more positive cytologic findings,
i.e. these were not subjects recruited from primary
screening. According to literature data, up to 8% of nega-
tive findings show positivity for p16INK4a, which is attrib-
uted to the morphologically recognizable positively stai-
ned atrophic, metaplastic, endocervical columnar or en-
dometrial cells7–9,38,41, whereby this positivity is weak
and recorded in a small number of cells in the group. The
lack of correspondence between p16INK4a expression and
HR HPV status in the ASC-H lesions under study could
be explained by difficulties in the interpretation of
p16INK4a stained atypical and immature metaplastic
cells42, although CIN III lesion was verified on biopsy in
one case of positive p16INK4a finding and negative HR
HPV result.
Conclusion
Based on our initial results, on detecting HSIL lesions
and carcinoma of uterine cervix, immunocytochemical
expression of the p16INK4a biomarker in ThinPrep cervi-
cal specimens correlates closely with the HR HPV typed
by the PCR method in the same sample. However, the
true value of adjunctive methods is their use in the triage
of patients with low-grade lesions and reduction in the
number of repeat cytology testing, unnecessary biopsies
and respective costs. We can assume that the combina-
tion of these tests can identify two groups within low-
-grade lesions, i.e. one with low risk for the development
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TABLE 2
CORRELATION BETWEEN p16INK4a TEST AND HR-HPV TEST
p16INK4a HR-HPV ASCUSN (%)
LSIL
N (%)
Negative Negative 4 (57.1) 3 (11.5)
Positive Negative 1 (14.3) 10 (38.5)
Negative Positive 1 (14.3) 5 (19.2)
Positive Positive 1 (14.3) 8 (30.8)
Total 7 26
HR – high -risk, HPV – human papillomavirus, ASCUS – atypi-
cal squamous cells of undetermined significance, LSIL – low-
-grade squamous intraepithelial lesions
of premalignant cervical lesions, for which both of these
tests are negative (57.1% ASCUS and 11.5% LSIL), and
another group of women with both tests positive (14.3%
ASCUS and 30.8% LSIL) and with the actual risk of
squamous intraepithelial lesions. A prospective study
with longer follow up may clarify their predictive values
in the LSIL and ASC diagnosis, especially in the groups
that have different test results of p16INK4a and HPV tests.
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TEKU]A CITOLOGIJA – NOVE MOGU]NOSTI U DIJAGNOSTICI LEZIJA VRATA MATERNICE
S A @ E T A K
Metoda teku}e citologije (engl. »liquid-based cytology«, LBC) omogu}uje primjenu dopunskih metoda u dijagnostici i
prognozi lezija vrata maternice. Cilj rada bio je usporedba imunocitokemijske ekspresije biomarkera p16INK4a u LBC-
-ThinPrep cervikalnim uzorcima u odnosu na HPV tipizaciju metodom polimeraze lan~ane reakcije (engl. »polymerase
chain reaction«, PCR). Ukupno 120 ThinPrep (Cytyc, USA) cervikalnih uzoraka obojenih metodom po Papanicolaouu
primarno su se analizirali primjenom citolo{ke klasifikacije »Zagreb 2002«, a na drugom ThinPrep preparatu istoga
uzorka napravljena je procjena ekspresije biomarkera p16INK4a pomo}u CINtec p16INK4a Cytology Kit (DakoCytomation,
D. Juri~ et al.: LBC in the Diagnosis of Cervical Lesions, Coll. Antropol. 34 (2010) 1: 19–24
23
Denmark). Pove}ana ekspresija onkogena E6 i E7 humanog papilomavirusa visokog rizika (engl. »high-risk human
papillomavirus«, HR HPV) rezultira porastom ekspresije proteina p16INK4a, ~iji se pozitivitet o~itava pojavom sme|ih
granula u jezgri i/ili citoplazmi abnormalnih stanica. Preostali LBC uzorak rabio se za HR HPV-DNA tipizaciju me-
todom PCR (AMPLICOR, Roche). Citolo{ki je klasificirano: 17 negativnih nalaza, 17 atipi~nih plo~astih stanica (ASC)
(7 ASC -neodre|enog zna~enja /ASCUS/ i 10 ASC- ne mo`e se isklju~iti skvamozna intraepitelna lezija visokog stupnja
/ASC-H/), 26 skvamoznih intraepitelnih lezija niskog stupnja (LSIL) tj. cervikalnih intraepitelnih neoplazija (CIN) I, 57
SIL visokog stupnja (HSIL) koji uklju~uju 24 CIN II i 33 CIN III, te 3 karcinoma plo~astih stanica. Imunocitokemijska
reakcija na p16INK4a bila je pozitivna u svim CIN III lezijama (11/11) i karcinomima (3/3), dok je HR HPV tipiziran u
97% (32/33) CIN III i 100% (3/3) karcinoma. Citolo{ki je identificiran p16INK4a u 87,5% (21/24) CIN II, te 69% (18/26)
CIN I, dok je HR HPV bio pozitivan u 75% (18/24) CIN II i 50% (13/26) CIN I. ASCUS promjene imale su istu stopu
pozitiviteta na p16INK4a i HR HPV (28,5%; 2/7), dok je u ASC-H promjenama p16INK4a bio pozitivan u svim slu~ajevima
(100%, 10/10), a HR HPV je tipiziran u svega 20% (2/10) lezija. Na temelju na{ih prvih rezultata mo`e se zaklju~iti da
imunocitokemijska ekspresija biomarkera p16INK4a u ThinPrep cervikalnim uzorcima usko korelira s HR HPV tipi-
ziranim metodom PCR iz istoga uzorka u otkrivanju HSIL lezija i karcinoma vrata maternice, dok su u procjeni LSIL i
ASC lezija potrebna daljnja morfolo{ko-molekularna pra}enja.
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